ArticleAntimicrobial agents and chemotherapy2003
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Guidelines for the management of adult lower respiratory tract infections--full version.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2011Guideline
- Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.Antimicrobial agents and chemotherapy · 2013Trial
- Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.Antimicrobial agents and chemotherapy · 2004Trial
- Carbohydrate-based drugs launched during 2000Acta pharmaceutica Sinica. B · 2022Review
- Anti-Mycoplasma Activity of Daptomycin and Its Use for Mycoplasma Elimination in Cell Cultures of Rickettsiae.Antibiotics (Basel, Switzerland) · 2019Article
- Mycoplasma pneumonia with hydropneumothorax: A case report.Respiratory medicine case reports · 2019Article
- Review
- Ureaplasma infection-mediated release of matrix metalloproteinase-9 and PGP: a novel mechanism of preterm rupture of membranes and chorioamnionitis.Pediatric research · 2017Article
- Mycoplasma pneumonia: Clinical features and management.Lung India : official organ of Indian Chest Society · 2010Article
- Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.Antimicrobial agents and chemotherapy · 2009Article
- Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.Drugs · 2008Review
- Mycoplasmas and ureaplasmas as neonatal pathogens.Clinical microbiology reviews · 2005Review
- Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.Antimicrobial agents and chemotherapy · 2005Article
- Mycoplasma pneumoniae and its role as a human pathogen.Clinical microbiology reviews · 2004Review
- Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro susceptibilities of 103 Mycoplasma pneumoniae isolates, 14 Mycoplasma hominis isolates, 12 Mycoplasma fermentans isolates, and 24 Ureaplasma species to ABT-773, an investigational ketolide, and seven other agents were determined. For M. pneumoniae, the ABT-773 MIC at which 90% of isolates are inhibited (MIC(90); <or=0.001 microg/ml) was comparable to those of azithromycin, clarithromycin, and erythromycin and at least 128-fold lower than those of levofloxacin, gatifloxacin, moxifloxacin, and doxycycline. For M. fermentans, the ABT-773 MIC(90) (<or=0.008 microg/ml) was 2- to 128-fold lower than those of all other agents tested. For M. hominis, the ABT-773 MIC(90) (0.031 microg/ml) was equivalent to that of moxifloxacin, 2-fold lower than those of gatifloxacin and clindamycin, and 16-fold lower than that of levofloxacin. ABT-773 was equally active against doxycycline-susceptible and doxycycline-resistant organisms. The ABT-773 MICs (0.016 microg/ml) for Ureaplasma species were the lowest of those of any drug tested. The MIC(90) was 4- to 64-fold lower than those of clarithromycin, azithromycin, and erythromycin and >or=16-fold lower than those of all three fluoroquinolones. Minimal bactericidal concentrations determined for a subgroup of organisms were <or=0.063 micro g/ml for M. pneumoniae and 0.25 microg/ml for M. fermentans, but they were several dilutions higher for M. hominis and Ureaplasma spp. ABT-773 has great potential for further study for the treatment of infections due to mycoplasmas and ureaplasmas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.